The ICON Cares 2025 Report is now live. Sharing progress across clinical research people, communities and ESG priorities. Read more: ow.ly/WHo650ZF35Q #ICONCares #ESG #ClinicalResearch #Sustainability #SDG3

Q: When should key COA decisions be made? A: Before the endpoint is locked. Learn how early #COA selection & development decisions can strengthen evidence, reduce risk + support regulatory strategy. Register for the webinar now: ow.ly/U4k950ZIEu8

How hard do you work to choose the right research publishing platform? Probably too hard. We can make it easier for you. PubsHub Journals and Congresses has information on over 10,000 entries with over 50 fields of data for each. Take a demo. ow.ly/S2Il50ZEopz

You've got 60 minutes with the FDA. Will you spend it answering questions or getting answers? Learn how AI-enabled #SaMD developers can prepare for a more productive FDA Pre-Sub meeting. ow.ly/hNPh50ZYlPe #AI #FDA #MedTech

Where can AI provide practical value in oncology development? Meet ICON at #ESMO26, booth #8005, to discuss applications across biomarkers, patient selection, trial design and evidence generation. Schedule a meeting: ow.ly/cTxf50ZTnYa

Approval does not guarantee reimbursement EMA marketing authorisation does not guarantee reimbursement. JCA evidence must address relative clinical effectiveness, safety and patient-relevant outcomes for European decision-making. ow.ly/Kn9A50ZYmcR

For drug developers advancing immunotherapies into chronic diseases, understanding the unique needs of different patient populations is essential. Explore key considerations across autoimmune disease, cardiometabolic conditions, and women’s health. ow.ly/Tmvv50ZTuAJ

Heading to Boston for The MedTech Conference? Meet ICON's MDDR team to discuss strategies for devices, diagnostics, wearables, digital health technologies and combination products, from development through post-market evidence generation. ow.ly/JQjI50ZLxAU #MTC26

Drop by booth #69 at #OCTNewEngland2026, 27– 28 October. Meet the ICON team to explore new solutions to common issues within clinical trials. ow.ly/SXsm50ZTpKJ

Join ICON at booth #6 at #OCTDACH, 3–4 November at the Congress Center, Basel. As a trusted partner to biotech and pharma across the DACH region, ICON delivers integrated clinical development solutions. ow.ly/b1Yj50ZTNK6

Cardiovascular innovation requires specialised expertise. ICON supports device sponsors from early feasibility through pivotal and post-market studies with dedicated medical device teams and deep therapeutic experience. See us at #MedTechCon. ow.ly/A0bU50ZKrek

ICON is heading to Copenhagen for #OCTNordics on 20–21 October. Stop by booth #41 to meet our team and explore how we’re supporting sponsors across the Nordics with faster, smarter, and more patient-focused clinical trials. Learn more: ow.ly/323E50ZIbyF

Liver disease research depends on reliable biomarkers and imaging endpoints. This #NationalLiverAwarenessMonth, discover how ICON's medical imaging expertise helps support MASH/MASLD studies with advanced quantitative imaging and global trial experience. ow.ly/H1aZ50ZWQQ6

Stay up-to-date with watchlists that you define. PubsHub Journals & Congresses watchlists send you updates on your priority list as updated information is available. Deadline changes, location confirmation, factors that affect your publishing decision. ow.ly/Y3Ig50ZEole

This October 15- 18, booth #406 at the #GSSS the Accellacare team will show you how it is providing clinical research as care option. ow.ly/Aglf50ZKr0g

ICON’s Dublin laboratory has achieved My Green Lab® Certification, earning Gold for Specialised Testing and Silver for Automated Areas. ow.ly/IGN350ZTT8L

We're looking forward to sharing new research at #ISPOREurope2026 covering outcomes assessment, regulatory science, systematic reviews, quality-of-life research and AI-enabled methodologies. Visit ICON at booth #1615. ow.ly/1WOx50ZUkNg #ISPOR #HEOR #EvidenceGeneration

Struggling to keep up with global regulatory change? ICON's Newsletter delivers the latest summaries of key updates from authorities including the FDA, EMA, MHRA and more. Subscribe for free today: ow.ly/MZrq50ZTuVc #RegulatoryIntelligence #RegulatoryAffairs

Observational data showing cross-protection from meningococcal B vaccines (like 4CMenB) provided a proof-of-concept for gonorrhoea prevention. Read the article to explore the evolving pipeline. ow.ly/LfMJ50ZUQ3J ow.ly/LfMJ50ZUQ3J

Autoimmune and chronic disease therapies face rising competition. Read the whitepaper to gain insights for sponsors bringing immunotherapies to the market in this space, including the regulatory landscape, timelines and indication selection. ow.ly/ngHo50ZTuyA

CSRs require scientific judgement, not just content generation. See why augmenting medical writers with AI can accelerate development while protecting quality: ow.ly/zxRg50ZL86m